STOCK TITAN

CervoMed: neuronal damage marker stable overall at 24 weeks

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

CervoMed presented 24-week interim biomarker findings from its Phase 2a trial of investigational neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA). In the U.S. cohort, 19 participants received open-label neflamapimod at 40 mg three times daily. Plasma neurofilament light chain (NfL), a biomarker of neuronal damage, remained stable overall and declined among participants whose plasma drug levels were in the upper third.

The 36-week study enrolled 25 participants: 19 in the U.S. cohort and six in a U.K. cohort receiving 80 mg twice daily. After 24 weeks of open-label dosing, the protocol provides for a 12-week double-blind, placebo-controlled randomized-withdrawal period, with participants assigned 1:1 to continue treatment or switch to placebo. The company expects U.K. cohort biomarker data in the first quarter of 2027 and clinical results at the AD/PD conference in March 2027.

Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Phase 2a trial enrollment 25 participants Total enrollment in the 36-week nfvPPA trial.
U.S. cohort enrollment 19 participants Received 40 mg three times daily in the open-label cohort.
U.S. cohort dose 40 mg three times daily Open-label neflamapimod regimen.
U.K. cohort enrollment 6 participants Assigned to the 80 mg twice-daily cohort.
U.K. cohort dose 80 mg twice daily Higher-dose cohort; biomarker data expected in the first quarter of 2027.
Interim biomarker period 24 weeks Reported interim data period for the U.S. cohort.
Randomized-withdrawal period 12 weeks Double-blind, placebo-controlled period following open-label dosing.
Expected U.K. cohort biomarker data First quarter of 2027 Expected readout for the 80 mg twice-daily cohort.
p38α inhibitor technical
"neflamapimod, an oral p38α inhibitor"
A p38α inhibitor is a drug or biological compound that blocks the activity of p38α, one of the p38 mitogen-activated protein kinase (MAPK) isoforms involved in cellular responses to stress and inflammation. By reducing p38α kinase signaling, these inhibitors can lower production of inflammatory molecules and alter cell survival and gene expression; many compounds differ in how selectively they target p38α versus other kinases or p38 isoforms, which affects their therapeutic effects and side‑effect profiles.
neurofilament light chain medical
"plasma neurofilament light chain (NfL), a key biomarker"
Neurofilament light chain is a protein released into cerebrospinal fluid and blood when nerve cells are damaged, acting like a measurable “leak” that signals injury to the brain or spinal cord. For investors, it matters because rising or falling levels can serve as an objective readout in clinical trials and disease monitoring, helping assess whether a drug or therapy is slowing nerve damage and reducing development or commercial risk.
randomized withdrawal medical
"12-week double-blind, placebo-controlled randomized withdrawal period"
A randomized withdrawal is a clinical trial design where people who initially get better on a treatment are later randomly assigned either to keep taking it or to stop, so researchers can measure whether benefits last and whether problems reappear. Think of testing a new routine by removing it for half the group to see if results continue. Investors care because these results reveal how durable a drug’s effects and safety profile are, which affect approval, labeling, prescribing and long-term sales.
trough plasma drug concentration medical
"a trough plasma drug concentration threshold"
Orphan Drug Designation regulatory
"Orphan Drug Designation for the treatment of frontotemporal dementia"
Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.
Fast Track Designation regulatory
"Fast Track Designation from the U.S. Food and Drug Administration"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CRVO report about neflamapimod in nfvPPA?

CervoMed reported that NfL remained stable overall over 24 weeks and declined among participants in the upper third for plasma neflamapimod levels. The interim results came from 19 U.S. participants receiving 40 mg three times daily.

When does CervoMed expect more nfvPPA trial results?

The company expects biomarker data from the U.K. 80 mg twice-daily cohort in the first quarter of 2027. It expects clinical results at the AD/PD conference in March 2027.

How is the CRVO Phase 2a nfvPPA trial designed?

The 36-week trial enrolled 25 participants. It includes 24 weeks of open-label treatment followed by a 12-week double-blind, placebo-controlled randomized-withdrawal period, with participants assigned 1:1 to continue neflamapimod or switch to placebo.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001053691 0001053691 2026-11-16 2026-11-16


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

 
FORM 8-K
 

 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
 
November 16, 2026
Date of Report (Date of earliest event reported)
 

 
CervoMed Inc.
(Exact name of registrant as specified in its charter)
 

 
Delaware
001-37942
30-0645032
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
 
 
20 Park Plaza, Suite 424
Boston, Massachusetts
02116
(Address of principal executive offices)
(Zip Code)
 
Registrant’s telephone number, including area code: (617) 744-4400
 
Not applicable
(Former name or former address, if changed since last report)
___________________________
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Title of each class
 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Common Stock, $0.001 par value
 
CRVO
 
NASDAQ Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
Item 7.01
Regulation FD Disclosure
 
Press Release
 
On November 16, 2026, CervoMed Inc. (the “Company”) issued a press release announcing the presentation of 24-week interim biomarker data from its ongoing Phase 2a clinical trial of neflamapimod in patients with nonfluent variant primary progressive aphasia  at the 19th Clinical Trials on Alzheimer’s Disease Conference. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
 
The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
 
Item 8.01
Other Events
 
The information set forth in the first paragraph and the information under the heading “24-Week Biomarker Data from the Phase 2a nfvPPA Study” of the Company’s press release referred to in Item 7.01 above is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.
 
Item 9.01
Financial Statements and Exhibits
 
(d)
Exhibits
 
The following exhibit relating to Item 7.01 is furnished and not filed:
 
Exhibit No.
Description
 
 
99.1
Press Release, issued November 16, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: November 16, 2026
CervoMed Inc.
 
 
 
 
 
 
By:
/s/ William Elder
 
 
Name:
William Elder
 
 
Title:
Chief Financial Officer & General Counsel
 
 
 

Exhibit 99.1

 

CervoMed Presents Interim Data at CTAD 2026 Showing Neflamapimod Reduces Neurodegeneration Biomarker in Nonfluent Variant Primary Progressive Aphasia

 

24-Week interim data shows neflamapimod delivered an exposure-dependent reduction in neurofilament light chain, a key biomarker of neuronal damage

 

Full 24-week biomarker and clinical data expected in the first quarter of 2027

 

Nonfluent variant primary progressive aphasia is a rare progressive neurodegenerative brain condition with no approved disease modifying treatments

 

 

BOSTON, November 16, 2026 — CervoMed Inc. (NASDAQ: CRVO) (CervoMed or the Company) today presented 24-week biomarker data from participants enrolled in the United States (U.S.) cohort of its Phase 2a clinical trial of neflamapimod, an oral p38α inhibitor, in nonfluent variant primary progressive aphasia (nfvPPA), a major subtype of frontotemporal dementia (FTD). Study participants who were in the upper third of plasma drug levels of neflamapimod showed a reduction in plasma neurofilament light chain (NfL), a key biomarker of neuronal damage that increases over time in patients with nfvPPA. The findings were presented at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference in Boston.

 

“Patients with nfvPPA progressively lose the ability to speak and, often in later stages of disease, develop movement and coordination issues. Today we have no approved therapies to offer them,” said Ian M. Grant, M.D., Assistant Professor of Neurology, Feinberg School of Medicine, Northwestern University and Phase 2a trial investigator. “NfL levels are one of the most reliable biomarkers we have of ongoing neurodegeneration in these patients, and it typically increases over time. Thus, overall stability in NfL levels and a reduction among participants with higher neflamapimod exposure provide early but meaningful signals of drug activity. These results add to the evidence that supports the potential of neflamapimod in the treatment of DLB, nfvPPA, and other neurodegenerative diseases.”

 

Interim 24-Week Biomarker Data from the Phase 2a nfvPPA Study 
The presentation included plasma NfL results for the 19 patients enrolled in the U.S., who received open-label treatment with 40 mg three times daily (TID) neflamapimod. 24-week biomarker data from the higher dose 80 mg twice daily (BID) cohort (N=6), enrolled in the United Kingdon (U.K.), will be available in the first quarter of 2027. Current results:

 

 

●

In the overall U.S. patient population (n=19) NfL levels remained stable over 24 weeks.

 


 

 

●

In a PK/PD analysis (n=18; trough plasma drug concentration, Ctrough, data not available in one participant), participants with neflamapimod Ctrough plasma levels in the upper tertile (n=6; Ctrough ≥4.5 ng/ml) showed a median 4.5 pg/mL reduction in NfL over 24 weeks. Participants with plasma drug concentrations in the lower two tertiles (n=12; Ctrough ≤3.5 ng/ml) showed a median increase in NfL of 4.35 pg/mL. This increase in NfL levels is consistent with the natural-history rate of approximately 9 pg/mL per year in untreated nfvPPA patients (Sheth et al., Molecular Neurodegeneration, 2025).

 

 

●

Neflamapimod was generally well tolerated, with no new safety signals identified.

 

“We’re encouraged by the 24-week neflamapimod biomarker data in nfvPPA, which provide an early biological signal and a path forward for the development of neflamapimod in nfvPPA.” said John Alam, M.D., Chief Executive Officer of CervoMed. “NfL rises rapidly over time in patients with nfvPPA, yet NfL levels remained stable overall, and participants who reached higher neflamapimod plasma levels showed a decline in NfL over 24 weeks. Importantly, the results are consistent with prior studies in dementia with Lewy bodies and Alzheimer’s disease that demonstrated a trough plasma drug concentration threshold for clinical and biomarker effect of approximately 4 ng/ml. We expect to report biomarker data from the 80 mg BID dose UK cohort and clinical results at the AD/PD conference in March 2027.”

 

The Phase 2a clinical trial of neflamapimod for the treatment of nfvPPA was designed to evaluate the safety, pharmacokinetics, and clinical effects of neflamapimod in participants with nfvPPA. The 36-week trial enrolled 25 participants and is being conducted at academic medical centers in the U.S. and U.K. The study includes 24 weeks of open-label treatment with neflamapimod 40 mg TID (n=19, enrolled in the US) or 80 mg BID (n=6, enrolled in the UK), followed by a 12-week double-blind, placebo-controlled randomized withdrawal period in which participants are assigned 1:1 to continue neflamapimod at the originally assigned dose or switch to placebo (ClinicalTrials.gov identifier: NCT07033481).

 

Neflamapimod Presentation at CTAD
Title: P045 - Initial neurodegeneration biomarker results from a Phase 2a clinical trial of neflamapimod in patients with nonfluent variant primary progressive aphasia

Authors: Ian M Grant1, Hugo Botha2, Lawerance S Honig3, Douglas W Scharre4, Amanda Gardner5, Kelly Blackburn5, Bradley F Boeve2, John J Alam5, David J Irwin6

Affiliations: 1Northwestern University, Chicago, United States, 2Mayo Clinic, Rochester, United States, 3Columbia University, New York, United States, 4Ohio State University, Columbus, United States, 5CervoMed, Boston, United States, 6University of Pennsylvania, Philadelphia, United States

 


 

The presentation of the results described above is accessible in the Events and Presentations section of CervoMed’s website, https://www.cervomed.com/.

 

About nfvPPA
nfvPPA, a type of frontotemporal dementia, gradually causes people with the condition to have trouble expressing themselves, although they still understand the meaning of words. Initially, they might use shorter phrases or pause while speaking and have difficulty pronouncing words. It can also be challenging for them to understand long or complex sentences. In advanced nfvPPA, people may stop speaking completely, and difficulty with planning and judgment, as well as moving, can occur.

 

There are an estimated 10,000-15,000 people living with nfvPPA in the U.S. and 15,000-20,000 in the European Union (E.U.). Currently, there are no approved treatments for nfvPPA in the U.S. or E.U.

 

About Neflamapimod
Neflamapimod is an investigational, orally administered small-molecule drug that readily crosses the blood-brain barrier and selectively inhibits the alpha isoform of p38 MAP kinase, a key driver of neuroinflammation and synaptic dysfunction. Preclinical research links p38α to tau-related neuronal deficits, supporting the study of neflamapimod in tau-driven forms of frontotemporal dementia such as nfvPPA.

 

By targeting the critical disease processes underlying degenerative disorders of the brain, neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies (DLB), recovery after ischemic stroke, nfvPPA, and amyotrophic lateral sclerosis (ALS).

 

Neflamapimod has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of DLB, and Orphan Drug Designation for the treatment of frontotemporal dementia, including its nfvPPA subtype.

 

CervoMed has developed a new 50 mg oral tablet form of the product that will allow dosing of neflamapimod at 100 mg BID, a dosage expected to yield in nearly all patients plasma concentrations at or above the observed pharmacological activity threshold. This tablet and dosing will be used in all future studies.

 

About CervoMed
CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without Alzheimer’s disease (AD) co-pathology. In November 2025, CervoMed announced alignment with the FDA on a potential registration path for neflamapimod in DLB, and the Company is currently focused on identifying a strategic partner to advance neflamapimod into a Phase 3 trial in DLB. CervoMed reported initial 12-week biomarker data from its ongoing Phase 2a clinical trial in nfvPPA in October 2026 and 24-week biomarker data in November 2026. The Company also expects to dose the first patient in the EXPERTS-ALS Phase 2a clinical trial in the first quarter of 2027.

 


 

Forward-Looking Statements
This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations, or forecasts for the future of the Company, including, but not limited to: the Company’s need to acquire sufficient funding, including funding (through a strategic partnership or otherwise) for any future trial in patients with DLB, and its ability to continue as a going concern; the Company’s plan to focus on strategic partnering to advance neflamapimod into Phase 3 for DLB and the timing of entering into any such partnership, if at all; the therapeutic potential of neflamapimod in DLB, nfvPPA, ALS, or any other indication, including the degree of sustainability of any therapeutic effects, its potential impact on the rate of disease progression and/or clinical worsening, the optimal dosing regimen to achieve therapeutic effects, or any other treatment effects observed in any clinical trial on any clinical, biomarker, or other outcome measure; the expected plasma drug concentrations to be achieved with the Company’s 50 mg tablet formulation and its planned use in future studies; the anticipated timing and achievement of clinical and development milestones, including the Company’s initiation of any Phase 3 trial in patients with DLB or the impact, if any, of the Innovation Passport Designation on any future regulatory milestone or the timing thereof; the anticipated data readouts from the Company’s Phase 2a trial in nfvPPA including the expected timing of biomarker data from the 80 mg BID cohort and clinical results, and the anticipated dosing of the first patient with neflamapimod in the EXPERTS-ALS trial; and any other expected or implied benefits, results, or expectations, including the extent (if any) to which neflamapimod may demonstrate efficacy or other clinical or biomarker improvements in patients with DLB, nfvPPA or in any other indication. Terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “aims,” “seeks,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential,” “target,” “project,” “contemplate,” “predict,” “forecast,” “continue,” or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company’s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company’s available cash resources, the availability of additional funds on acceptable terms or at all, and the Company’s ability to continue as a going concern; the results of the Company’s clinical trials, including the risk that interim data may change as more data becomes available and may not be predictive of future results; the Company’s ability to successfully enter into a partnership to advance neflamapimod into Phase 3 for DLB in a timely manner, on acceptable terms, or at all; the timing of enrollment, dosing, and data readouts in the Company’s clinical trials; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the FDA or other regulators; the Company’s ability to maintain the intellectual property protection afforded by the Company’s patent portfolio; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the US Securities and Exchange Commission (SEC) on March 13, 2026, and the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the SEC on November 6, 2026, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.

 

 

Contacts

 

Media:
Biongage Communications
lisa.guiterman@gmail.com
202-330-3431

 

Investor Relations:
Argot Partners
cervomed@argotpartners.com
212-600-1902 

 

Filing Exhibits & Attachments

5 documents

Keep reading